Moneycontrol PRO
UPCOMING EVENT:Join us for New HorAIzon from Oct 6-7, 2pm and be a part of exciting conversations on tech & innovation

Hold Dr Reddy’s Laboratories: target of Rs 5250: ICICI Direct

ICICI Direct recommended hold rating on Dr Reddy’s Laboratories with a target price of Rs 5250 in its research report dated July 28, 2021.

August 02, 2021 / 11:27 AM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Dr Reddy’s Laboratories

Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and differentiated formulations. Revenue: US (37%), India (18%), Russia and CIS (12%), Europe (8%), RoW (6%) and API (16.8%) It has 13 formulation facilities, nine API manufacturing facilities, one biologics facility and several R&D centres across the globe


We retain our HOLD rating on the stock We value Dr Reddy’s at Rs 5250 i.e. 25x P/E on FY23E + Rs 317.2 for NPV of gRevlimid and Sputnik.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 2, 2021 11:27 am

stay updated

Get Daily News on your Browser
ISO 27001 - BSI Assurance Mark